Familial Mediterranean FeverNCT05596643
Investigation of Autonomic Dysfunction in Patients With Familial Mediterranean Fever
An observational study of Familial Mediterranean Fever and Autonomic Dysfunction, run by Marmara University at 1 site in Turkey (Türkiye).
Trial summary
Familial Mediterranean Fever (FMF) is the most common inherited autoinflammatory disease affecting 150,000 patients worldwide. Periodic febrile exacerbations, peritonitis, and pleuritis are characteristic disease features. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Familial Mediterranean Fever, Autonomic Dysfunction
- What is being tested?
- Composite Autonomic Symptom Score-31, r-r interval variability with normal breathing and r-r interval variability with deep breathing
- How many people
- 60 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Mar 2022to 31 Oct 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients with FMF Healthy control group
Who may be able to join
- Familial Mediterranean Fever group;
- Being between the ages of 18-65
- Having a definite diagnosis of Familial Mediterranean Fever according to Livneh criteria
- Healthy control group;
- Being between the ages of 18-65
- Absence of any disease diagnosis
Who cannot join
- Liver or kidney failure
- Pregnancy
- Diabetes mellitus
- Thyroid diseases
- Those who use neuroprotective or antihypertensive drugs
- Vitamin B12 deficiency
Show all 14Show fewer
- Anemia
- Paraneoplastic neuropathy
- Alcoholism
- Cardiac failure
- Cardiac arrhythmia
- Acute thrombosis
- Having a diagnosis of another systemic rheumatic disease
- Persons who did not give consent to participate in the study
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Marmara University School of Medicine, Pendik Education and Research Hospital, Department of Physical Medicine and Rehabilitation
Istanbul
İmran Kalkan, +90 530 340 5594, imrankalkann55@gmail.com
Mehmet Tuncay Duruöz, Prof
About this study
Familial Mediterranean Fever (FMF) is the most common inherited autoinflammatory disease affecting 150,000 patients worldwide. Periodic febrile exacerbations, peritonitis, and pleuritis are characteristic disease features. Dysregulation of IL-1β secretion has an important role in the pathophysiology of the disease, and IL-1β also serves as a therapeutic target. Chronic inflammation has been associated with early atherosclerotic and cardiovascular disease in various rheumatic diseases. An increased risk for cardiovascular events associated with disease activity has been described in rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. In addition, autonomic nervous system dysfunction may contribute to increased cardiovascular risk in patients with inflammatory disease. For example, decreased heart rate variability is an important feature of cardiac autonomic dysfunction and is an isolated risk factor for cardiovascular events. Autonomic dysfunction studies related to FMF have conflicting results.
The aim of this study was to determine autonomic dysfunction symptoms and objective findings in patients with FMF; Demographic characteristics, disease characteristics, inflammatory burden, fatigue level, sleep quality, presence of fibromyalgia and their relationship with quality of life were evaluated and compared with healthy controls.
- Being tested
- Composite Autonomic Symptom Score-31, r-r interval variability with normal breathing, r-r interval variability with deep breathing, Valsalva ratio, 30:15 ratio
- Keywords
- Familial Mediterranean Fever, Autonomic Dysfunction, r-r interval variability, sympathetic skin response
- Medical subject headings
- Familial Mediterranean Fever, Primary Dysautonomias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Composite Autonomic Symptom Score-31Diagnostic test
Also called COMPASS-31
Standardized questionnaire to determine the level of autonomic dysfunction
r-r interval variability with normal breathingDiagnostic test
electrophysiological test to detect parasympathetic dysfunction
r-r interval variability with deep breathingDiagnostic test
electrophysiological test to detect parasympathetic dysfunction
Valsalva ratioDiagnostic test
electrophysiological test to detect parasympathetic dysfunction
30:15 ratioDiagnostic test
electrophysiological test to detect parasympathetic dysfunction
sympathetic skin responseDiagnostic test
Also called SSR
electrophysiological test to detect sympathetic dysfunction
blood pressure response to standingDiagnostic test
clinical test to detect sympathetic dysfunction
blood pressure response to sustained handgrip testDiagnostic test
clinical test to detect sympathetic dysfunction
Hospital anxiety and depression scaleOther
Also called HADS
Standardized questionnaire to investigate the depression and anxiety
Fibromyalgia rapid screening toolDiagnostic test
Also called FIRST
Standardized questionnaire to determine the presence of fibromyalgia
Familial Mediterranean Fever Quality of life scaleOther
Also called FMFQoL
Standardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients
Jenkins Sleep Evaluation ScaleOther
Standardized questionnaire to investigate the sleep quality and disturbance
The Fatigue Severity ScaleOther
Also called FSS
Standardized questionnaire to investigate the fatigue severity
| Study group | Role | What they receive |
|---|---|---|
| Patients diagnosed with Familial Mediterranean Fever | Not described Receives: Diagnostic Test: Composite Autonomic Symptom Score-31; Diagnostic Test: r-r interval variability with normal breathing; Diagnostic Test: r-r interval variability with deep breathing; Diagnostic Test: Valsalva ratio; Diagnostic Test: 30:15 ratio; Diagnostic Test: sympathetic skin response; Diagnostic Test: blood pressure response to standing; Diagnostic Test: blood pressure response to sustained handgrip test; Other: Hospital anxiety and depression scale; Diagnostic Test: Fibromyalgia rapid screening tool; Other: Familial Mediterranean Fever Quality of life scale; Other: Jenkins Sleep Evaluation Scale; Other: The Fatigue Severity Scale | |
| Healthy Controls | Not described Receives: Diagnostic Test: Composite Autonomic Symptom Score-31; Diagnostic Test: r-r interval variability with normal breathing; Diagnostic Test: r-r interval variability with deep breathing; Diagnostic Test: Valsalva ratio; Diagnostic Test: 30:15 ratio; Diagnostic Test: sympathetic skin response; Diagnostic Test: blood pressure response to standing; Diagnostic Test: blood pressure response to sustained handgrip test; Other: Hospital anxiety and depression scale; Diagnostic Test: Fibromyalgia rapid screening tool; Other: Jenkins Sleep Evaluation Scale; Other: The Fatigue Severity Scale |
What is being measured
The primary outcome is the main question the study is designed to answer.
Composite Autonomic Symptom Score-31
It is a widely applicable, up-to-date, easy-to-apply and scientifically-based test that evaluates autonomic symptoms and functions by the person himself. It consists of 31 multiple-choice questions in 6 autonomic areas: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder function and pupillomotor areas. A score in the range of 0-100 is obtained as a result of multiplying each area by the weight factor determined by the study. High score indicates presence and severity of autonomic dysfunction.
Measured: 6 months
r-r interval variability with normal breathing
The active and reference superficial recording electrodes are on the dorsal side of both hands, and the ground electrode is placed on the wrist. The R-R interval variability is calculated automatically by the electromyography device over a 1-minute recording.
Measured: 6 months
r-r interval variability with deep breathing
The active and reference superficial recording electrodes are on the dorsal side of both hands, and the ground electrode is placed on the wrist. In order to determine the R-R interval variability with deep breathing, the patient is given 6 to 8 deep breaths, consisting of 5 seconds of inspiration followed by 5 seconds of expiration, and the result is automatically calculated by the electromyography device.
Measured: 6 months
Valsalva ratio
The active and reference superficial recording electrodes are on the dorsal side of both hands, and the ground electrode is placed on the wrist. The test was performed by asking the subject to sit quietly and then blow into a mouthpiece attached to an aneroid pressure gauge at a pressure of 40 mmHg for 15 seconds. The ratio of the longest R-R interval shortly after the manoeuver (within about 20 beats) and the shortest R-R interval during the manoeuver is then measured. The result was expressed as the Valsalva ratio that is taken as the mean ratio from three successive Valsalva manoeuvers.
Measured: 6 months
30:15 ratio
The active and reference superficial recording electrodes are on the dorsal side of both hands, and the ground electrode is placed on the wrist.The R-R interval on the ECG was recorded and used to determine the instantaneous HR at rest and then on the 15th and 30th beats after standing. The HR should normally rise after about 30 seconds as part of the response to return the blood pressure (BP) to normal. After standing up, the 30:15 ratio obtained by dividing the longest R-R distance around the 30th beat by the shortest R-R distance around the 15th beat was calculated automatically by the EMG device.
Measured: 6 months
sympathetic skin response
Sweating that occurs in response to many different stimuli, electrolyte in the skin triggers changes in skin conductivity, resulting in instantaneous changes in skin conductivity. Sympathetic skin response evaluates these instantaneous changes in the skin in response to sweating. Sympathetic skin response reflects the function of sympathetic nerve fibers.Active recording electrodes on palm and sole; reference electrodes is placed on the back of the hand and the back of the foot. Responses obtained by applying electrical current over the median nerve trace are evaluated.
Measured: 6 months
blood pressure response to standing
Participants were asked to stand up for 3 minutes after a 10-minute resting period in a supine position. The systolic and diastolic BP (SBP and DBP) just before standing, and 3 minutes after active standing were determined, in order to define postural change in BP and to evaluate orthostatic intolerance.
Measured: 6 months
blood pressure response to sustained handgrip
Blood pressure measurement is continued at 1-minute intervals while patients perform sustained handgip at 30% of their maximum volitional strength for 5 minutes.The absolute difference between the highest DBP during handgrip and the basal DBP just before the handgrip was noted.
Measured: 6 months
Secondary outcomes (5)
Familial Mediterranean Fever Quality of Life Scale (FMF-QoL)
FMF-QoL was developed to evaluate the quality of life in FMF patients. This scale consists of 20 questions in the form of a Likert scale and the total scoring is between 0-80. High scores indicate a decrease in quality of life.
Measured: 6 months
Hospital Anxiety and Depression Scale (HADS)
This scale consists of 14 questions in total, and anxiety symptoms are questioned in half of the questions and depression-related complaints in the other half. A subscore of 8 or higher for depression or anxiety is considered a clinical case.
Measured: 6 months
Fibromyalgia Rapid Screening Tool (FIRST)
This scale consists of 6 questions investigating the most relevant clinical features of fibromyalgia. The questions are answered as yes/no and 5 or more out of 6 points in total are in favor of fibromyalgia.
Measured: 6 months
The Fatigue Severity Scale (FSS)
It consists of a total of 9 questions in which complaints related to fatigue are scored between 0 and 7, taking into account the fatigue in the last week. The mean score is obtained by dividing the total score by 9, and it is defined as <4.0 points as no fatigue, 4.0-5.0 points at the border, and >5.0 points as fatigue.
Measured: 6 months
Jenkins Sleep Evaluation Scale (JSS)
It is a scale in which scores between 0 and 5 are made for each symptom by questioning how many days in a month 4 sleep-related symptoms are experienced considering the last 1 month. The total score is between 0-20, and as the score increases, sleep quality deteriorates.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Oct 2022
- Study start15 Mar 2022
- Primary completion31 Oct 2022 (estimated)
- Study completion31 Oct 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Familial Mediterranean FeverStudies of the same condition, open and under way.
- More trials run by Marmara UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Marmara University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Mehmet Tuncay Duruöz, Prof, Principal investigator, Marmara University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05596643
- Sponsor's protocol ID
- 09.2021.1427
- Status last verified
- Oct 2022
- First submitted
- 24 Oct 2022
- Last updated
- 27 Oct 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of Autonomic Dysfunction in Patients With Familial Mediterranean Fever
- ClinicalTrials.gov ID
- NCT05596643
- Acronym / sponsor ID
- 09.2021.1427
- Keywords
- Familial Mediterranean Fever, Autonomic Dysfunction, r-r interval variability, sympathetic skin response
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Marmara UniversityUniversity, hospital or other
- Study start
- 15 Mar 2022 (actual)
- Primary completion
- 31 Oct 2022 (estimated)
- Study completion
- 31 Oct 2022 (estimated)
- First posted
- 27 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Familial Mediterranean Fever (FMF) is the most common inherited autoinflammatory disease affecting 150,000 patients worldwide. Periodic febrile exacerbations, peritonitis, and pleuritis are characteristic disease features. Dysregulation of IL-1β secretion has an important role in the pathophysiology of the disease, and IL-1β also serves as a therapeutic target. Chronic inflammation has been associated with early atherosclerotic and cardiovascular disease in various rheumatic diseases. An increased risk for cardiovascular events associated with disease activity has been described in rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. In addition, autonomic nervous system dysfunction may contribute to increased cardiovascular risk in patients with inflammatory disease. For example, decreased heart rate variability is an important feature of cardiac autonomic dysfunction and is an isolated risk factor for cardiovascular events. Autonomic dysfunction studies related to FMF have conflicting results.
The aim of this study was to determine autonomic dysfunction symptoms and objective findings in patients with FMF; Demographic characteristics, disease characteristics, inflammatory burden, fatigue level, sleep quality, presence of fibromyalgia and their relationship with quality of life were evaluated and compared with healthy controls.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients diagnosed with Familial Mediterranean Fever | – | Diagnostic Test: Composite Autonomic Symptom Score-31, Diagnostic Test: r-r interval variability with normal breathing, Diagnostic Test: r-r interval variability with deep breathing, Diagnostic Test: Valsalva ratio, Diagnostic Test: 30:15 ratio, Diagnostic Test: sympathetic skin response, Diagnostic Test: blood pressure response to standing, Diagnostic Test: blood pressure response to sustained handgrip test, Other: Hospital anxiety and depression scale, Diagnostic Test: Fibromyalgia rapid screening tool, Other: Familial Mediterranean Fever Quality of life scale, Other: Jenkins Sleep Evaluation Scale, Other: The Fatigue Severity Scale |
| Healthy Controls | – | Diagnostic Test: Composite Autonomic Symptom Score-31, Diagnostic Test: r-r interval variability with normal breathing, Diagnostic Test: r-r interval variability with deep breathing, Diagnostic Test: Valsalva ratio, Diagnostic Test: 30:15 ratio, Diagnostic Test: sympathetic skin response, Diagnostic Test: blood pressure response to standing, Diagnostic Test: blood pressure response to sustained handgrip test, Other: Hospital anxiety and depression scale, Diagnostic Test: Fibromyalgia rapid screening tool, Other: Jenkins Sleep Evaluation Scale, Other: The Fatigue Severity Scale |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with FMF Healthy control group
Key inclusion criteria (6 listed)
- Familial Mediterranean Fever group;
- Being between the ages of 18-65
- Having a definite diagnosis of Familial Mediterranean Fever according to Livneh criteria
- Healthy control group;
- Being between the ages of 18-65
Key exclusion criteria (14 listed)
- Liver or kidney failure
- Pregnancy
- Diabetes mellitus
- Thyroid diseases
- Those who use neuroprotective or antihypertensive drugs
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Composite Autonomic Symptom Score-31Also: COMPASS-31Standardized questionnaire to determine the level of autonomic dysfunction | Diagnostic test | Healthy Controls, Patients diagnosed with Familial Mediterranean Fever |
| r-r interval variability with normal breathingelectrophysiological test to detect parasympathetic dysfunction | Diagnostic test | Healthy Controls, Patients diagnosed with Familial Mediterranean Fever |
| r-r interval variability with deep breathingelectrophysiological test to detect parasympathetic dysfunction | Diagnostic test | Healthy Controls, Patients diagnosed with Familial Mediterranean Fever |
| Valsalva ratioelectrophysiological test to detect parasympathetic dysfunction | Diagnostic test | Healthy Controls, Patients diagnosed with Familial Mediterranean Fever |
| 30:15 ratioelectrophysiological test to detect parasympathetic dysfunction | Diagnostic test | Healthy Controls, Patients diagnosed with Familial Mediterranean Fever |
| sympathetic skin responseAlso: SSRelectrophysiological test to detect sympathetic dysfunction | Diagnostic test | Healthy Controls, Patients diagnosed with Familial Mediterranean Fever |
| blood pressure response to standingclinical test to detect sympathetic dysfunction | Diagnostic test | Healthy Controls, Patients diagnosed with Familial Mediterranean Fever |
| blood pressure response to sustained handgrip testclinical test to detect sympathetic dysfunction | Diagnostic test | Healthy Controls, Patients diagnosed with Familial Mediterranean Fever |
| Hospital anxiety and depression scaleAlso: HADSStandardized questionnaire to investigate the depression and anxiety | Other | Healthy Controls, Patients diagnosed with Familial Mediterranean Fever |
| Fibromyalgia rapid screening toolAlso: FIRSTStandardized questionnaire to determine the presence of fibromyalgia | Diagnostic test | Healthy Controls, Patients diagnosed with Familial Mediterranean Fever |
| Familial Mediterranean Fever Quality of life scaleAlso: FMFQoLStandardized questionnaire to investigate the quality of life in Familial Mediterranean Fever patients | Other | Patients diagnosed with Familial Mediterranean Fever |
| Jenkins Sleep Evaluation ScaleStandardized questionnaire to investigate the sleep quality and disturbance | Other | Healthy Controls, Patients diagnosed with Familial Mediterranean Fever |
| The Fatigue Severity ScaleAlso: FSSStandardized questionnaire to investigate the fatigue severity | Other | Healthy Controls, Patients diagnosed with Familial Mediterranean Fever |
Primary outcome
Composite Autonomic Symptom Score-31
Time frame: 6 months
It is a widely applicable, up-to-date, easy-to-apply and scientifically-based test that evaluates autonomic symptoms and functions by the person himself. It consists of 31 multiple-choice questions in 6 autonomic areas: orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder function and pupillomotor areas. A score in the range of 0-100 is obtained as a result of multiplying each area by the weight factor determined by the study. High score indicates presence and severity of autonomic dysfunction.
r-r interval variability with normal breathing
Time frame: 6 months
The active and reference superficial recording electrodes are on the dorsal side of both hands, and the ground electrode is placed on the wrist. The R-R interval variability is calculated automatically by the electromyography device over a 1-minute recording.
r-r interval variability with deep breathing
Time frame: 6 months
The active and reference superficial recording electrodes are on the dorsal side of both hands, and the ground electrode is placed on the wrist. In order to determine the R-R interval variability with deep breathing, the patient is given 6 to 8 deep breaths, consisting of 5 seconds of inspiration followed by 5 seconds of expiration, and the result is automatically calculated by the electromyography device.
Valsalva ratio
Time frame: 6 months
The active and reference superficial recording electrodes are on the dorsal side of both hands, and the ground electrode is placed on the wrist. The test was performed by asking the subject to sit quietly and then blow into a mouthpiece attached to an aneroid pressure gauge at a pressure of 40 mmHg for 15 seconds. The ratio of the longest R-R interval shortly after the manoeuver (within about 20 beats) and the shortest R-R interval during the manoeuver is then measured. The result was expressed as the Valsalva ratio that is taken as the mean ratio from three successive Valsalva manoeuvers.
30:15 ratio
Time frame: 6 months
The active and reference superficial recording electrodes are on the dorsal side of both hands, and the ground electrode is placed on the wrist.The R-R interval on the ECG was recorded and used to determine the instantaneous HR at rest and then on the 15th and 30th beats after standing. The HR should normally rise after about 30 seconds as part of the response to return the blood pressure (BP) to normal. After standing up, the 30:15 ratio obtained by dividing the longest R-R distance around the 30th beat by the shortest R-R distance around the 15th beat was calculated automatically by the EMG device.
sympathetic skin response
Time frame: 6 months
Sweating that occurs in response to many different stimuli, electrolyte in the skin triggers changes in skin conductivity, resulting in instantaneous changes in skin conductivity. Sympathetic skin response evaluates these instantaneous changes in the skin in response to sweating. Sympathetic skin response reflects the function of sympathetic nerve fibers.Active recording electrodes on palm and sole; reference electrodes is placed on the back of the hand and the back of the foot. Responses obtained by applying electrical current over the median nerve trace are evaluated.
blood pressure response to standing
Time frame: 6 months
Participants were asked to stand up for 3 minutes after a 10-minute resting period in a supine position. The systolic and diastolic BP (SBP and DBP) just before standing, and 3 minutes after active standing were determined, in order to define postural change in BP and to evaluate orthostatic intolerance.
blood pressure response to sustained handgrip
Time frame: 6 months
Blood pressure measurement is continued at 1-minute intervals while patients perform sustained handgip at 30% of their maximum volitional strength for 5 minutes.The absolute difference between the highest DBP during handgrip and the basal DBP just before the handgrip was noted.
5 secondary outcomes
Familial Mediterranean Fever Quality of Life Scale (FMF-QoL)
Time frame: 6 months
Hospital Anxiety and Depression Scale (HADS)
Time frame: 6 months
Fibromyalgia Rapid Screening Tool (FIRST)
Time frame: 6 months
The Fatigue Severity Scale (FSS)
Time frame: 6 months
Jenkins Sleep Evaluation Scale (JSS)
Time frame: 6 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2022.
- Individual participant dataSharing planned: No
Related trials for Familial Mediterranean Fever
RecruitingObservational study
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics
Familial Mediterranean Fever (FMF), Autoinflammation
RecruitingPhase 3
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Behçet's Disease, Juvenile Psoriatic Arthritis
Not yet recruitingPhase 3
Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever
Familial Mediterranean Fever, FMF
Not yet recruitingObservational study
Genotype and Phenotype in Pediatric Familial Mediterranean Fever
Familial Mediterranean Fever
Not yet recruitingObservational study
Serum EBI-3 Protein Levels in Behçet's Disease
Behçet Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mehmet Tuncay Duruöz, Prof principal investigator
Marmara University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Familial Mediterranean Fever and Autonomic Dysfunction, run by Marmara University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 27 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact İmran Kalkan (+90 530 340 5594, imrankalkann55@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Composite Autonomic Symptom Score-31 (time frame: 6 months). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2022.